Pham Quang X, who serves as both CEO and Chairman of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), recently sold 1,165 shares of the company's common stock on May 22, 2026. This disposition amounted to a total value of $6,628, with the selling price for the shares ranging between $5.60 and $5.82.
The sale was structured as part of a Rule 10b5-1 trading arrangement, a mechanism that Mr. Pham adopted on September 25, 2025. Following this reported direct disposition, records show that Mr. Pham currently holds a remaining balance of 194,924 shares of Cadrenal Therapeutics common stock.
Market observers note that the timing of this insider sale contrasts with the current trading price of the stock, which is $5.19, falling below the range at which the recent transaction occurred. Furthermore, the company's stock performance over the past year has shown a decline of 63.5%, and its year-to-date performance reflects a decrease of 23.45%.
Financial Health and Corporate Structure
Analysis from InvestingPro indicates that Cadrenal Therapeutics is currently consuming cash rapidly, reflected by a